Small molecule · Inhibitor of B-cell lymphoma 2 (BCL-2) protein (BCL2) · developed by Beone Medicines Usa
Sonrotoclax is an orally bioavailable BCL-2 inhibitor that binds the anti-apoptotic protein B-cell lymphoma 2 and displaces pro-apoptotic proteins, restoring apoptosis in BCL-2-overexpressing cancer cells.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 27, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06073821 | Phase 3 | CLL | Active not recruiting | ONC |
| NCT07628881 | Phase 1 | Healthy Volunteers | Completed | ONC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CLLHealthy Volunteers
Updated Nov 15, 2026. Something wrong or missing? Report it on the ONC page.
See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ONC catalysts and pipeline →